3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Lymphoid
1651
Other hematologic neoplasm
704
Dermatologic
259
Plasma cell
254
Myeloid
226
Sarcoma
158
CNS
88
Genitourinary
75
Classical hematology
73
Gynecologic
66
Breast
65
Other neoplasm
35
Thoracic
32
Gastrointestinal
27
Head & Neck
14
Endocrine
7
Other solid neoplasm
6
Other
6
NET
2
Conditions
Neuroendocrine Tumors
394
Carcinoid Tumor
49
Gastro-enteropancreatic neuroendocrine tumor
42
Neoplasms
36
Carcinoma, Neuroendocrine
36
Adenoma, Islet Cell
27
Neoplasm Metastasis
23
Pancreatic Neoplasms
22
Colorectal Neoplasms
21
Pheochromocytoma
20
Paraganglioma
19
Sarcoma
15
Gastrointestinal Neoplasms
15
Carcinoma
14
Breast Neoplasms
14
Stomach Neoplasms
13
Prostatic Neoplasms
13
Neuroblastoma
13
Lung Neoplasms
13
Carcinoma, Hepatocellular
13
Thyroid Neoplasms
12
Small Cell Lung Carcinoma
12
Carcinoma, Renal Cell
11
Cholangiocarcinoma
10
Neuroectodermal Tumors, Primitive
9
Carcinoma, Non-Small-Cell Lung
9
Somatostatinoma
8
Serotonin Syndrome
8
Digestive System Neoplasms
8
Brain Neoplasms
8
Interventions
pasireotide
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Lymphoma, Follicular
×
NET
×
Clear all
NCT06784752
2026-04-30
NETTER-3
Novartis
Phase 3
Recruiting
240 enrolled
NCT02113800
2020-10-28
EVINEC
AIO-Studien-gGmbH
Phase 2
Completed
40 enrolled